ClinicalTrials.Veeva

Menu

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

S

Sanguine Biosciences

Status

Enrolling

Conditions

Non Small Cell Lung Cancer

Treatments

Diagnostic Test: Specimen sample

Study type

Observational

Funder types

Industry

Identifiers

NCT05669105
SAN-08877

Details and patient eligibility

About

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants willing and able to provide written informed consent
  • Participants are willing and able to provide appropriate photo identification
  • Participant's age 18 - 100 years old
  • Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
  • Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion criteria

  • Participants who are pregnant or nursing
  • Participants with a known history of HIV, hepatitis, or other infectious diseases
  • Participants who have taken an investigational product in the last 30 days
  • Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
  • Participants currently enrolled in a clinical trial
  • Participants currently in remission

Trial contacts and locations

1

Loading...

Central trial contact

Thomas Goslin

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems